Roche partnership brings $700M upfront for NRx BTK degrader
Roche partnership expands the clinical and commercial reach of a BTK degrader, with $700M upfront and up to $2.3B in milestones.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.